Early use of genome sequencing (GS) in the diagnostic odyssey can reduce suffering and improve care, but questions remain about which patient populations are most amenable to GS as a first-line ...
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results